Sangamo Therapeutics Raises $25M in Complex Warrant Offering — Sangamo Therapeutics, Inc.

Event summary

$25M raised via underwritten offering of common stock and warrants at $0.4719 per share.
35.2M shares of common stock and pre-funded warrants sold with accompanying purchase warrants.
Exercise price reduced on outstanding warrants for key investor from $1.00 to $0.4719.
Proceeds earmarked for working capital and general corporate purposes.
Offering expected to close February 4, 2026.

The big picture

Sangamo's unconventional offering—combining stock, pre-funded warrants, and exercise price adjustments—signals aggressive financial maneuvering in the cash-intensive genomic medicine space. The $25M raise comes amid broader biotech sector challenges with R&D funding and clinical timelines, highlighting the trade-offs between immediate liquidity needs and long-term equity dilution.

What we're watching

Liquidity Strategy: How Sangamo will deploy the $25M to extend runway amid cash burn pressures.
Investor Sentiment: Whether warrant terms reflect desperation or strategic flexibility in capital structure.
Clinical Milestones: The pace at which pipeline progress can justify current valuation metrics.